Obesity GLP-1 Market Analysis - Size, Share, and Forecast Outlook 2025 to 2035 Industry Size (2025): USD 8169 Mn Forecast (2035): USD 65364 Mn CAGR (2025 to 2035): 23.1% Obesity GLP-1 Market Forecast and Outlook 2025 to 2035 The obesity GLP-1 market is projected to grow from USD 8169 million in 2025 to approximately USD 65,364 million by 2035, recording an absolute increase of USD 57,195 million over the forecast period
Kaufman said he was particularly considering doing so in his more severely patients
6 In contrast, Yoshida and colleagues found through a meta-analysis of 4 CVOTsincluding trials that specifically showed cardiovascular benefit of GLP-1RAs and excluding trials testing off-market GLP-1RAsthat GLP-1RA was associated with retinopathy complications after 52 weeks on the drug
State and federal pharmacy regulations do not permit the return of dispensed prescription medications
Dose escalation schedules are brand-specificfor example, Wegovy (semaglutide for weight management) follows a weekly titration schedule, while Saxenda (liraglutide for weight management) has a daily titration protocol
